Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 70,345	$ 36,665
Marketable investments	63,259	90,217
Accounts receivables, net	24,715	18,715
Inventory	20,697	8,106
Prepaid expenses	8,960	11,804
Other current assets	8,072	7,482
Total current assets	196,048	172,989
Property and equipment, net	42,530	41,325
Operating lease right-of-use assets	86,094	85,173
Intangibles, net	172,566	259,705
Goodwill	81,351	79,525
Equity investments	50,739	51,271
Other assets, net	2,804	4,830
Total assets	632,132	694,818
Current liabilities:
Accounts payable	24,937	27,414
Accrued payroll and related benefits	28,394	21,503
Accrued expenses	45,816	37,975
Current portion of deferred revenue	1,018	1,108
Current portion of operating lease liabilities	13,508	11,539
Current portion of contingent consideration	397	397
Acquisition consideration	7,537	7,537
Current portion of debt	23,714	31,980
Total current liabilities	145,321	139,453
Long-term debt, net of discount	83,069	110,627
Deferred tax liabilities, net	2,358	2,426
Deferred revenue	117,445	118,942
Derivative liabilities	500	35,700
Operating lease liabilities	84,316	83,431
Contingent consideration	57,949	124,349
Other long-term liabilities	5,411	1,761
Total liabilities	496,369	616,689
Commitments and contingencies (See Note 10)
Sorrento Therapeutics, Inc. equity
Common stock, $0.0001 par value 750,000,000 shares authorized and 436,418,964 and 314,573,225 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	18	32
Additional paid-in capital	1,826,810	1,513,758
Accumulated other comprehensive income	837	1,026
Accumulated deficit	(1,646,178)	(1,386,604)
Treasury stock, 7,568,182 shares at cost at June 30, 2022, and December 31, 2021	(49,464)	(49,464)
Total Sorrento Therapeutics, Inc. stockholders’ equity	132,023	78,748
Noncontrolling interests	3,740	(619)
Total equity	135,763	78,129
Total liabilities and stockholders’ equity	$ 632,132	$ 694,818